Racura Oncology (ASX:RAC) said a third patient in its CPACS phase one clinical trial in advanced solid tumors was dosed with 40 milligrams per square meter of RC220, its proprietary formulation of bisantrene, at the first Hong Kong site, completing the recruitment of the first trial group, according to a Thursday Australian bourse filing.

No phlebitis or any other adverse events were reported following the dosing. The safety review committee will review all accumulated safety data collected from the three patients.

The first stage of the trial is using ascending doses of the drug candidate to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients. The effects on a range of clinical biomarkers, including a blood-based measure of the cardioprotective mechanism of action of RC220, will also be examined.

Its shares jumped 12% in recent trading on Thursday.